AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01242475 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 TU Tuberculin PPD RT 23 SSI
Description: The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
Study NCT00775749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch
Description: The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
Study NCT00775749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
Study NCT02078284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPP
Description: One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
Study NCT02078284 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LSP
Study NCT02932280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
Study NCT02854436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.
Study NCT00627627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
Study NCT03355859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR029
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
Study NCT03985033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: leucocyte and platelet-rich fibrin (L-PRF)
Description: The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
Study NCT04998253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effects in oxygenation and hypoxic pulmonary vasoconstriction
Description: Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution.
Study NCT04998253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effects in oxygenation and hypoxic pulmonary vasoconstriction
Description: Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution.
Study NCT01901146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 980
Description: ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Study NCT01901146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Study NCT01901146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
Study NCT01901146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
Study NCT01901146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection
Study NCT01901146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection
Study NCT01497873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: 1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
Study NCT01497873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotecan
Description: 0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
Study NCT03241849 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modified surgical technique for placenta accreta
Description: suturing of the myometrium splitted by the placenta in cases presented by placenta accreta
Study NCT02044302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT02917837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual QCNL DI utilization report
Description: See arm descriptions.
Study NCT02917837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual QCNL DI utilization report
Description: See arm descriptions.
Study NCT02917837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New DI utilization report
Description: See arm descriptions.
Study NCT02917837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detailing
Description: In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
Study NCT04240821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline ER
Description: Oral theophylline
Study NCT01304836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: oral
Study NCT01304836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT01304836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT02328001 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Debriefing endoscopists of the procedure accessory costs
Description: Informing endoscopists of the number of accessories used and the dollar value of the accessories
Study NCT00087399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Study NCT00087399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antidepressant
Study NCT00913471 — intervention group
Intervention type: OTHER
Intervention: blood samples
Description: Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.
Study NCT00581386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LTS-D
Description: supra-glottic airway device
Study NCT00581386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway
Description: pre-existing double-lumen supra-glottic device
Study NCT00581386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Tracheal Combitube (ETC)
Description: disposable double-lumen tube
Study NCT02773888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study NCT02762968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules similar to the experimental treatments.
Study NCT02762968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Capsules containing calcium HMB.
Study NCT02762968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BC30
Description: Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
Study NCT01883999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® EXCLUDER® Iliac Branch Endoprosthesis
Study NCT03522090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lower neck CT
Description: Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
Study NCT01304836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT01304836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Description: IV
Study NCT01304836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simulect
Description: IV
Study NCT01304836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: IV \& oral
Study NCT01304836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV \& oral
Study NCT02961972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: monohydrate and micronized creatine
Description: oral supplementation with creatine
Study NCT02961972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral supplementation with maltodextrin (control group)
Study NCT01568047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily
Study NCT01568047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 5 mg single-dose
Study NCT01568047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 15 mg single-dose
Study NCT01568047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 30 mg single-dose
Study NCT01568047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg
Study NCT01568047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg
Study NCT01568047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg
Study NCT01568047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg
Study NCT00874029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halt Procedure
Description: The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
Study NCT05698420 — intervention group
Intervention type: DEVICE
Intervention: Dialysis using the Theranova-400 device.
Description: Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
Study NCT05698420 — intervention group
Intervention type: DEVICE
Intervention: Dialysis using the FX80 device.
Description: Patients receive hemodialysis treatment using the FX80 dialyzer.
Study NCT02595528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
Study NCT02595528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
Study NCT02595528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 vehicle
Description: Vehicle to AGN-190584
Study NCT02595528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 + AGN-190584 Combination
Description: 1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
Study NCT04112147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol capsule 100mg
Description: Patients will receive 12-week of 50mg BID Antroquinonol
Study NCT04112147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol capsule 200mg
Description: Patients will receive 12-week of 100mg BID Antroquinonol
Study NCT02044302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins
Study NCT02044302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Study NCT02044302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics
Study NCT03011827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibrinogen and/or platelets administration
Description: Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
Study NCT04112147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will receive 12-week of 100mg BID Antroquinonol placebo
Study NCT00324623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A VLP vaccine, IMP321 adjuvant
Study NCT00324623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adoptive immunotherapy
Study NCT00324623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Study NCT00324623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00324623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT02287103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping Breakfast
Description: NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
Study NCT02287103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eating Breakfast
Description: YesB: will eat all three meals
Study NCT00246636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antara (fenofibrate) + Lovaza
Description: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Study NCT00246636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antara (fenofibrate)
Description: Antara (fenofibrate) + placebo
Study NCT00246636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antara (fenofibrate)
Description: Antara (fenofibrate) + placebo
Study NCT04276545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV administration of DEX to investigate the effects for functional nasal endoscopic surgery
Description: IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
Study NCT04276545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV administration of DEX to investigate the effects for functional nasal endoscopic surgery
Description: IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
Study NCT04276545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery
Description: IV administration of midazolam (0.05mg/kg) after induction.
Study NCT04276545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery
Description: IV administration of midazolam (0.05mg/kg) after induction.
Study NCT02595528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 vehicle
Description: Vehicle to AGN-199201
Study NCT00633321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-NIC
Description: TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
Study NCT00633321 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
Study NCT01947946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive.
Study NCT01947946 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 44 inclusive.
Study NCT01659723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
Study NCT02252211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8895a 1 mg/kg
Description: Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Study NCT02252211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8895a 3 mg/kg
Description: Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Study NCT02252211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8895a 10 mg/kg
Description: Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Study NCT03116594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of Oka/SK strain of live, attenuated zoster virus
Study NCT03116594 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Preparation of Oka/Merck strain of live, attenuated zoster virus
Study NCT06042829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation using aerosol box
Description: Intubation time and ease of intubation using aerosol box
Study NCT06042829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation without aerosol box
Description: Intubation time and ease of intubation without aerosol box
Study NCT01985126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg (Part 1)
Description: Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
Study NCT01985126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 8 mg/kg (Part 1)
Description: Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
Study NCT01985126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted